



## JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office. T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)  
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-46181100, 46109900  
CIN No L74899DL1978PLC009181

Date: July 29<sup>th</sup>, 2020

To, The Department of Corporate Services- Listing <b>Bombay Stock Exchange Ltd,</b> Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001	To, The Manager- Listing <b>National Stock Exchange of India Ltd</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051
<b>Scrip Code: 507789</b>	<b>Symbol: JAGSNPHARM</b>

**SUBJECT:- OUTCOME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON JULY 29<sup>th</sup>, 2020**

Dear Sir,

We wish to inform you that the Board of Directors of the Company at their meeting held today, (i.e. Wednesday, the 29<sup>th</sup> Day of July, 2020), have inter alia, approved and taken on record the followings:

1. Audited Standalone Financial Results of the Company for the Quarter and year ended 31st March, 2020 along with Audit Report.
2. Declaration pursuant to Regulation 33 (3) (d) of the Listing Regulations.
3. The Board recommended Dividend @ 10% on Equity shares of Rs. 5/- each.
4. Un-Audited Financial Results of the Company for the Quarter ended 30<sup>th</sup> June, 2020;
5. Limited Review Report for the Quarter ended 30<sup>th</sup> June, 2020;
6. Notice of 41<sup>st</sup> Annual General Meeting;
7. Draft Director's Report together with management discussion along with Report on Corporate Governance;
8. Availment of E- Voting facility from NSDL.
9. Appointment of Scrutinizer for conducting E-voting.
10. Fixed the Book Closure date and cut- off date for the purpose of Annual General Meeting and e-voting.

Kindly take the above on record & oblige.

For JAGSONPAL PHARMACEUTICALS LIMITED

  
  
Nandita Singh  
Company Secretary & Compliance Officer  
A48520



## JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office. T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)  
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-46181100, 46109900  
CIN No. L74899DL1978PLC009181

To, The Department of Corporate Services- Listing <b>Bombay Stock Exchange Ltd,</b> Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001	To, The Manager- Listing <b>National Stock Exchange of India Ltd</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051
<b>Scrip Code: 507789</b>	<b>Symbol: JAGSNPHARM</b>

**Subject:-** Declaration pursuant to the Regulation 33(3) (d) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 in respect of Audit Reports with unmodified opinion on Audited Financial Results ended 31<sup>st</sup> March, 2020.

Dear Sir,

In terms of Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that Statutory Auditors of the Company, M/s H.L. Bansal & Co. Chartered Accountants (Firm Registration No. 008563N) have issued an Audit Report with unmodified opinion on Audited Financial Results of the Company for the quarter and financial year ended March 31, 2020.

**For Jagsonpal Pharmaceuticals Limited**

Rajpal Singh Kochhar  
Managing Director  
DIN: 00059492

Sanjiv Kumar Dudeja  
Chief Financial Officer



## INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF JAGSONPAL PHARMACEUTICALS LIMITED

Report on the Indian Accounting Standards (Ind AS) Financial Statements

1. We have audited the accompanying Ind AS financial statements of Jagsonpal Pharmaceuticals Limited ("the Company"), which comprise the Balance Sheet as at March 31, 2020, the Statement of Profit and Loss (including Other Comprehensive Income), the Cash Flow Statement, Statement of changes in Equity and a summary of the significant accounting policies and other explanatory information.

Management's Responsibility for the Ind AS Financial Statements

2. The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Ind AS financial statements to give a true and fair view of the financial position, financial performance (including other comprehensive income), cash flows and changes in Equity of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards specified in the Companies (Indian Accounting Standards) Rules, 2015 (as amended) under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

### Auditors' Responsibility

3. Our responsibility is to express an opinion on these Ind AS financial statements based on our audit.
4. We have taken into account the provisions of the Act and the Rules made there under including the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.
5. We conducted our audit of the Ind AS financial statements in accordance with the Standards on Auditing specified under Section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Those Standards and pronouncements require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Ind AS financial statements are free from material misstatement.
6. An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Ind AS financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the Ind AS financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the Ind AS financial





statements that give a true and fair view, in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the Ind AS financial statements.

7. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Ind AS financial statements.

### Opinion

8. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Ind AS financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the Ind AS and other accounting principles generally accepted in India, of the state of affairs of the Company as at March, 31, 2020, and its total comprehensive income (comprising of Profit and other comprehensive income), its cash flows, the changes in Equity of the company and a summary of significant accounting policies and other explanatory information for the year ended on that date.

### **Report on Other Legal and Regulatory Requirements**

9. As required by the Companies (Auditor's Report) Order, 2016, issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act ("the Order"), and on the basis of such checks of the books and records of the Company as we considered appropriate and according to the information and explanations given to us, we give in the Annexure B a statement on the matters specified in paragraphs 3 and 4 of the Order.
10. As required by Section 143 (3) of the Act, we report that:
  - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books,
  - (c) The Balance Sheet, the Statement of Profit and Loss (including other comprehensive income), the Cash Flow Statement and changes in Equity Report are in agreement with the books of account
  - (d) In our opinion, the aforesaid Ind AS financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act.
  - (e) On the basis of the written representations received from the directors as on March 31, 2020 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2020 from being appointed as a director in terms of Section 164 (2) of the Act.
  - (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in Annexure A.
  - (g) With respect to the other matters to be included in the Auditors' Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our knowledge and belief and according to the information and explanations given to us:
    - i. The Company has disclosed the impact, if any of pending litigations as at March 31, 2020 on its financial position in its Ind AS financial statements - Refer Note 24





- ii. The Company did not have any long-term contracts including derivative contracts as at March 31,2020.
- iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company during the year ended March 31, 2020.

**For H L Bansal & Co.  
Chartered Accountants  
(Firm's Registration No. 008563N**

  


**HIRA LAL BANSAL  
Partner  
(Membership No. 086990)**

Place : Delhi  
Date : 29/07/2020

## ANNEXURE A TO INDEPENDENT AUDITORS' REPORT

### **Referred to in paragraph 10(f) of the Independent Auditors' report of even date to the Members of Jagsonpal Pharmaceuticals Limited on the Ind AS financial statements for the year ended March 31, 2020**

#### **Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Act**

1. We have audited the internal financial controls over financial reporting of Jagsonpal Pharmaceuticals Limited ("the Company") as of March 31, 2020 in conjunction with our audit of the Ind AS financial statements of the Company for the year ended on that date.

#### **Management's Responsibility for Internal Financial Controls**

2. The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

#### **Auditors' Responsibility**

3. Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing deemed to be prescribed under section 143(10) of the Act to the extent applicable to an audit of internal financial controls, both applicable to an audit of internal financial controls and both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.
4. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining and understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.
5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.





### Meaning of Internal Financial Controls Over Financial reporting

6. A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

### Inherent Limitations of Internal Financial Controls Over Financial Reporting

7. Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial control over financial reporting to future periods are subject to the risk that the internal financial controls over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### Opinion

8. In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2020, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For H L Bansal & Co.  
Chartered Accountants  
(Firm's Registration No. 008563N)**

  
  
**HIRA LAL BANSAL  
Partner  
(Membership No. 086990)**

Date : 29/07/2020

Place : Delhi

## ANNEXURE B TO INDEPENDENT AUDITORS' REPORT

**Referred to in paragraph 9 of the Independent Auditors' report of even date to the Members of Jagsonpal Pharmaceuticals Limited on the Ind AS financial statements as of and for the year ended March 31, 2020**

i (a) The Company is maintaining proper records showing full particulars, including quantitative details and situation, of fixed assets.

(b) The fixed assets are physically verified by the Management according to a phased programme designed to cover all the items over a period of three years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the programme, a portion of the fixed assets has been physically verified by the Management during the year and no material discrepancies have been noticed on such verification.

(c) The title deeds of immovable properties as disclosed in Note 3 on Property, Plant and Equipment to the Ind AS financial statements, are held in the name of the Company,

ii. The Inventory except for goods in transit has been physically verified by the management at reasonable intervals during the year .In respect of inventory lying with third parties, to the extent, such inventories have not been physically verified by the management, such inventories have been substantially confirmed by the third parties. The discrepancies noticed on physical verification of inventory as compared to book records were not material and have been appropriately dealt with in the books of accounts .

iii. The Company has not granted any loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or other parties covered in the register maintained under Section 189 of the Act. Therefore, the provisions of Clause 3(iii), (iii)(a), (iii)(b) and (iii)(c) of the said Order are not applicable to the Company.

iv. The Company has not granted any loans or provided any guarantees or security to the parties covered under section 185 of the Act. The company has complied with the provisions of section 186 of the Act in respect of investments made to the parties covered under section 186 of the Act.

v. The Company has not accepted any deposits from the public within the meaning of Sections 73, 74, 75 and 76 of the Act and the Rules framed there under to the extent notified.

vi. Pursuant to the rules made by the Central Government of India, the Company is required to maintain cost records as specified under Section 148(1) of the Act in respect of its products. We have broadly reviewed the same, and are of the opinion that, prima facie, the prescribed accounts and records have been made and maintained. We have not, however, made a detailed examination of the records with a view to determine whether they are accurate or complete.

vii. (a) According to the information and explanations given to us and the records of the Company examined by us, in our opinion, the Company is generally regular in depositing the undisputed statutory dues, including provident fund, employees' state insurance, income tax, sales tax, service tax, customs duty, excise duty ,value added tax, Goods and Service Tax , cess and other material statutory dues, as applicable, with the appropriate authorities.

(b) According to the information and explanations given to us and the records of the Company examined by us, the particulars of dues of income tax, sales tax, service tax, duty of customs and duty of excise value added tax as at March 31, 2020 which have not been deposited on account of a dispute, are as follows:





**ANNEXURE OF CASE PENDING WITH VAT/SALES TAX AND OTHER LAWS**

<b>Nature of the statute</b>	<b>Nature of dues</b>	<b>Amount</b>	<b>Period to which the amount relates</b>	<b>Forum where the dispute is pending</b>
Vat/Sale Tax Pune	Demand	1,79,53,179	2014 15	Sale Tax Authority
Vat/Sale Tax Pune	Demand	3,43,29,747	2015 16	Sale Tax Authority
Vat/Sale Tax Kolkata	-----do-----	29,04,851	2008-2009	-----do-----
-----do-----	-----do-----	21,31,250	2008-2009 (CST)	-----do-----
-----do-----	-----do-----	16,70,707	2009-2010	-----do-----
Vat/Sale Tax Cochin	-----do-----	2,73,632	2014-2015	-----do-----
		10,53,344	2015-16	
		2,40,722	2016-17	
<b>Total</b>		<b>6,05,57,432</b>		

viii. The Company has neither availed any loans or borrowings from any financial institution or bank or Government, nor has it issued any debentures as at the balance sheet date, the provisions of Clause 3(viii) of the Order are not applicable to the Company.

ix. The Company has not raised any moneys by way of initial public offer, further public offer (including debt instruments) and term loans. Accordingly, the provisions of Clause 3(ix) of the Order are not applicable to the Company.

x. During the course of our examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practices in India, and according to the information and explanations given to us, we have neither come across any instance of material fraud by the Company or on the Company by its officers or employees, noticed or reported during the year, nor have we been informed of any such case by the Management.

xi. The Company has paid/provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of Section 197 read with Schedule V to the Act.

xii. As the Company is not a Nidhi Company and the Nidhi Rules, 2014 are not applicable to it, the provisions of Clause 3(xii) of the Order are not applicable to the Company.

xiii. The Company has entered into transactions with related parties in compliance with the provisions of Sections 177 and 188 of the Act. The details of such related party transactions have been disclosed in the



Ind AS financial statements as required under Indian Accounting Standard (IndAS) Note 24, Related Party Disclosures specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

xiv. The Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review. Accordingly, the provisions of Clause 3(xiv) of the Order are not applicable to the Company.

xv. The Company has not entered into any non-cash transactions with its directors or persons connected with them. Accordingly, the provisions of Clause 3(xv) of the Order are not applicable to the Company.

xvi. The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, the provisions of Clause 3(xvi) of the Order are not applicable to the Company.

**For H L Bansal & Co.  
Chartered Accountants  
(Firm's Registration No. 008563N)**



**HIRA LAL BANSAL  
Partner  
(Membership No. 086990)**

Place : Delhi  
Date : 29/07/2020



**Statement of Standalone Audited Financial Results for the Quarter and Year Ended 31.03.2020**

Rs. in lakhs

Particulars	Standalone			12 Months	12 Months
	Quarter Ended			Year Ended	Year Ended
	31.03.2020	31.03.2019	31.12.2019	31.03.2020	31.03.2019
	Audited	Audited	Unaudited	Audited	Audited
<b>1 Income from operations</b>					
a Gross Sales/Revenue from Operations	2951.75	3840.22	4201.04	15856.78	16682.56
b Other Operating Income	0.00	0.00	0.00	0.00	0.00
<b>Total Income from operations</b>	2951.75	3840.22	4201.04	15856.78	16682.56
<b>2 Other Income</b>	76.04	87.95	65.08	252.62	142.90
<b>3 Total Income [ 1+2]</b>	<b>3027.79</b>	<b>3928.17</b>	<b>4266.12</b>	<b>16109.40</b>	<b>16825.46</b>
<b>4 Expenses</b>					
a Cost of materials consumed	505.01	746.34	1244.12	3678.48	3878.66
b Purchases of stock-in-trade	343.96	539.39	535.02	1815.19	1464.08
c Changes in inventories of finished goods, work in progress and Stock in trade	-66.62	101.19	-380.60	124.99	1941.82
d Employee benefits expenses	1014.37	1059.88	1461.64	5037.42	4661.10
e Finance Cost	14.71	27.31	10.12	51.41	74.55
f Depreciation and amortisation expense	31.70	28.13	25.95	112.98	101.58
g Other expenses	1032.68	1052.23	1084.46	4347.45	3803.39
<b>Total expenses</b>	<b>2875.81</b>	<b>3554.47</b>	<b>3980.71</b>	<b>15167.92</b>	<b>15925.18</b>
<b>5 Profit before exceptional items and taxes (3-4)</b>	<b>151.98</b>	<b>373.70</b>	<b>285.41</b>	<b>941.48</b>	<b>900.28</b>
6 Exceptional Items	0.00	0.00	0.00	0.00	0.00
<b>7 Profit before tax [5-6]</b>	<b>151.98</b>	<b>373.70</b>	<b>285.41</b>	<b>941.48</b>	<b>900.28</b>
8 Tax expense	-3.50	76.24	57.09	154.40	178.67
<b>9 Net Profit for the period [7-8]</b>	<b>155.48</b>	<b>297.46</b>	<b>228.32</b>	<b>787.08</b>	<b>721.61</b>
10 Other Comprehensive Income					
A (i) Items that will not be classified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00
<b>11 Total Other Comprehensive Income [A(i) + A(ii)]</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>12 Total Comprehensive Income [9+11]</b>	<b>155.48</b>	<b>297.46</b>	<b>228.32</b>	<b>787.08</b>	<b>721.61</b>
13 Paid up Equity Share Capital (Face value Rs. 5/- per share)	1309.90	1309.90	1309.90	1309.90	1309.90
<b>14 Earnings Per Share (before and after extraordinary items)</b>					
(of Rs 5/- each)					
a. Basic (Rs.)	0.59	1.14	0.87	3.00	2.75
b. Diluted (Rs.)	0.59	1.14	0.87	3.00	2.75



Statement of Assets and Liabilities		
Particulars	As on 31.03.2020	As on 31.03.2019
<b>ASSETS</b>		
<b>1 Non-current assets</b>		
(a) Property , Plant and Equipment	2206.02	2161.39
(b) Capital Work-in-Progress	190.34	189.15
(c) Goodwill	3.00	3.00
(d) Intangible assets under development	234.53	206.27
(e) Financial assets		
(i) Investments	1138.68	0.05
(f) Other non-current assets	1431.91	1262.72
<b>Total non-current assets</b>	<b>5204.48</b>	<b>3822.58</b>
<b>2 Current assets</b>		
(a) Inventories	2932.50	3269.26
(b) Financial assets		
(i) Trade receivables	2145.34	2075.02
(ii) Cash and Cash equivalents	27.75	35.70
(iii) Bank balances other than (ii) above	3779.67	3817.76
(c) Other current assets	605.75	558.09
<b>Total current assets</b>	<b>9491.01</b>	<b>9755.83</b>
<b>TOTAL ASSETS</b>	<b>14695.49</b>	<b>13578.41</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
(a) Equity Share Capital	1309.90	1309.90
(b) Other Equity		
(i) Reserves & Surplus	9793.49	9137.41
<b>Total Equity</b>	<b>11103.39</b>	<b>10447.31</b>
<b>LIABILITIES</b>		
<b>1 Non-current liabilities</b>		
(a) Deferred tax liabilities (Net)	309.16	311.91
(b) Non current borrowings		
<b>Non-current liabilities</b>	<b>309.16</b>	<b>311.91</b>
<b>2 Current Liabilities</b>		
(a) Financial Liabilities		
(i) Trade payables	1170.93	1186.04
(ii) Short term borrowings	466.48	378.54
(b) Other current liabilities	815.56	559.97
(c) Provision for tax	829.97	694.64
<b>Total current liabilities</b>	<b>3282.94</b>	<b>2819.19</b>
<b>Total Liabilities</b>	<b>3592.10</b>	<b>3131.10</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>14695.49</b>	<b>13578.41</b>





**NOTES:**

1. The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on June 30, 2020. The statutory auditors have expressed an unmodified opinion on the aforesaid results,

2. In line with the provisions of Ind AS 18, the Company operates in one reportable business segment i.e. 'Pharmaceuticals'.

3. Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.

4. The above results are available on website of the company [www.jagsonpal.com](http://www.jagsonpal.com) and on the Website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)).

5. The Company has adopted Ind AS from April 1, 2017 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder.

6. The outbreak of Coronavirus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. Businesses are being forced to cease or limit their operations for long or indefinite period of time. Measures taken to contain the spread of the virus, including travel bans, quarantines, social distancing, and closures of non-essential services have triggered significant disruptions to businesses worldwide, resulting in an economic slowdown. COVID-19 is significantly impacting business operation of the companies, by way of interruption in production, supply chain disruption, unavailability of personnel, closure / lock down of production facilities etc. On 24th March 2020, the Government of India ordered a nationwide lockdown for 21 days which further got extended till 3rd May 2020 to prevent community spread of COVID-19 in India resulting in significant reduction in economic activities.

7. Provision for taxation includes provision for current tax.

8. The Board of Directors has proposed a dividend of Rs 0.50 per Equity Shares of Rs 5/- each.

9. Figures for the quarter ended 31st March 2020 are balancing figures between the audited figures in respect of full financial year ended 31st March 2020 and published figure upto 3rd quarter ended 31st December 2019.



By Order of the Board  
For Jagsonpal Pharmaceuticals Limited

A handwritten signature in blue ink, appearing to read 'Rajpal Singh Kochhar'.

Place : New Delhi  
Date : 29 July, 2020

Rajpal Singh Kochhar  
Managing Director  
DIN No 00059492





## LIMITED REVIEW REPORT

The Board of Directors  
Jagsonpal Pharmaceuticals Limited  
T-210-J, Shahpur Jat  
New Delhi-110049

1. We have reviewed the accompanying statement of Unaudited Financial Results of Jagsonpal Pharmaceuticals Limited (the "Company") for the Quarter ended 30th June, 2020. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 29th July 2020  
Place: New Delhi

For H. L. Bansal & Co.  
Firm Registration Number: 008563N  
Chartered Accountants

  
Hira Lal Bansal  
Partner

Membership Number: 086990

**Statement of Standalone Unaudited Financial Results for the Quarter ended 30.06.2020**

Rs. in lacs

Particulars	Standalone			12 Months
	Quarter Ended			Year Ended
	30.06.2020	31.03.2020	30.06.2019	31.03.2020
	Unaudited	Audited	Unaudited	Audited
<b>1 Income from operations</b>				
a Gross Sales/Revenue from Operations	3165.21	2951.75	4523.40	15856.78
b Other Operating Income	0.00	0.00	0.00	0.00
<b>Total Income from operations</b>	<b>3165.21</b>	<b>2951.75</b>	<b>4523.40</b>	<b>15856.78</b>
<b>2 Other Income</b>	<b>78.45</b>	<b>76.04</b>	<b>67.12</b>	<b>252.62</b>
<b>3 Total Income [ 1+2]</b>	<b>3243.66</b>	<b>3027.79</b>	<b>4590.52</b>	<b>16109.40</b>
<b>4 Expenses</b>				
a Cost of materials consumed	440.2	505.01	1173.13	3678.48
b Purchases of stock-in-trade	234.74	343.96	474.83	1815.19
c Changes in inventories of finished goods, work in progress and Stock in trade	579.69	-66.62	201.11	124.99
e Employee benefits expenses	1181.98	1014.37	1314.51	5037.42
f Finance Cost	13.09	14.71	11.77	51.41
g Depreciation and amortisation expense	27.45	31.70	28.61	112.98
h Other expenses	463.98	1032.68	1136.10	4347.45
<b>Total expenses</b>	<b>2941.13</b>	<b>2875.81</b>	<b>4340.06</b>	<b>15167.92</b>
<b>5 Profit before exceptional items and taxes (3-4)</b>	<b>302.53</b>	<b>151.98</b>	<b>250.46</b>	<b>941.48</b>
6 Exceptional Items	0.00	0.00	0.00	0.00
<b>7 Profit before tax [5-6]</b>	<b>302.53</b>	<b>151.98</b>	<b>250.46</b>	<b>941.48</b>
8 Tax expense	50.50	-3.50	50.09	154.40
<b>9 Net Profit for the period [7-8]</b>	<b>252.03</b>	<b>155.48</b>	<b>200.37</b>	<b>787.08</b>
10 Other Comprehensive Income				
A (i) Items that will not be classified to profit or loss	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00
<b>11 Total Other Comprehensive Income [A(i) + A(ii)]</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>12 Total Comprehensive Income [9+11]</b>	<b>252.03</b>	<b>155.48</b>	<b>200.37</b>	<b>787.08</b>
13 Paid up Equity Share Capital (Face value Rs. 5/- per share)	1309.90	1309.90	1309.90	1309.90
<b>14 Earnings Per Share (before and after extraordinary items) (of Rs 5/- each)</b>				
a. Basic (Rs.)	0.96	0.59	0.76	3.00
b. Diluted (Rs.)	0.96	0.59	0.76	3.00

**Notes**

- The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on July 29, 2020.
- In line with the provisions of Ind AS 18, the Company operates in one reportable business segment i.e. 'Pharmaceuticals'.
- Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.
- The above results are available on website of the company [www.jagsonpal.com](http://www.jagsonpal.com) and on the Website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)).
- The Company has adopted Ind AS from April 1, 2017 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder.
- The revenue for the quarter ended 30-6-2020, is reported net of GST.
- Provision for taxation includes provision for current tax.



Place : New Delhi  
Date : 29-7-2020

By Order of the Board  
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar  
Managing Director  
DIN No 00059492